NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Adamas Pharmaceuticals Inc (NASDAQ: ADMS)
ADMS Technical Analysis
1
As on N/A ADMS SHARE Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS. |
ADMSSHARE Price
Open | N/A | Change | Price | % |
High | N/A | 1 Day | N/A | N/A |
Low | N/A | 1 Week | N/A | N/A |
Close | N/A | 1 Month | N/A | N/A |
Volume | N/A | 1 Year | N/A | N/A |
52 Week High N/A | 52 Week Low N/A |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
ADMS Daily Charts |
ADMS Intraday Charts |
Whats New @ Bazaartrend |
ADMS Free Analysis |
|
ADMS Important Levels Intraday
RESISTANCE | |
RESISTANCE | |
RESISTANCE | |
RESISTANCE | |
RESISTANCE | |
RESISTANCE | |
RESISTANCE | |
RESISTANCE |
ADMS Forecast April 2024
4th UP Forecast | |
3rd UP Forecast | |
2nd UP Forecast | |
1st UP Forecast | |
1st DOWN Forecast | |
2nd DOWN Forecast | |
3rd DOWN Forecast | |
4th DOWN Forecast |
ADMS Weekly Forecast
4th UP Forecast | |
3rd UP Forecast | |
2nd UP Forecast | |
1st UP Forecast | |
1st DOWN Forecast | |
2nd DOWN Forecast | |
3rd DOWN Forecast | |
4th DOWN Forecast |
ADMS Forecast2024
4th UP Forecast | |
3rd UP Forecast | |
2nd UP Forecast | |
1st UP Forecast | |
1st DOWN Forecast | |
2nd DOWN Forecast | |
3rd DOWN Forecast | |
4th DOWN Forecast |
Adamas Pharmaceuticals Inc ( NASDAQ USA Symbol : ADMS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ADMS Other Details
Segment | EQ | |
Market Capital | 371006848.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
ADMS Address
ADMS Latest News
ADMS Business Profile
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Address: 1900 Powell Street, EmeryVille, CA, United States, 94608
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service